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A bs tr ac t
Background
Although we know that exacerbations are key events in chronic obstructive pulmo-
nary disease (COPD), our understanding of their frequency, determinants, and effects 
is incomplete. In a large observational cohort, we tested the hypothesis that there is 
a frequent-exacerbation phenotype of COPD that is independent of disease severity.
Methods
We analyzed the frequency and associations of exacerbation in 2138 patients en-
rolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-
points (ECLIPSE) study. Exacerbations were defined as events that led a care pro-
vider to prescribe antibiotics or corticosteroids (or both) or that led to hospitalization 
(severe exacerbations). Exacerbation frequency was observed over a period of 3 years.
Results
Exacerbations became more frequent (and more severe) as the severity of COPD 
increased; exacerbation rates in the first year of follow-up were 0.85 per person for 
patients with stage 2 COPD (with stage defined in accordance with Global Initiative 
for Chronic Obstructive Lung Disease [GOLD] stages), 1.34 for patients with stage 
3, and 2.00 for patients with stage 4. Overall, 22% of patients with stage 2 disease, 
33% with stage 3, and 47% with stage 4 had frequent exacerbations (two or more 
in the first year of follow-up). The single best predictor of exacerbations, across all 
GOLD stages, was a history of exacerbations. The frequent-exacerbation phenotype 
appeared to be relatively stable over a period of 3 years and could be predicted on 
the basis of the patient’s recall of previous treated events. In addition to its asso-
ciation with more severe disease and prior exacerbations, the phenotype was inde-
pendently associated with a history of gastroesophageal reflux or heartburn, poorer 
quality of life, and elevated white-cell count.
Conclusions
Although exacerbations become more frequent and more severe as COPD progresses, 
the rate at which they occur appears to reflect an independent susceptibility pheno-
type. This has implications for the targeting of exacerbation-prevention strategies 
across the spectrum of disease severity. (Funded by GlaxoSmithKline; ClinicalTrials 
.gov number, NCT00292552.) 
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The natural history of chronic ob-structive pulmonary disease (COPD) is punc-tuated by exacerbations — acute worsening 
of symptoms. Exacerbations appear to accelerate 
the decline in lung function that characterizes 
COPD,1,2 resulting in reduced physical activity,3 
poorer quality of life,4 and an increased risk of 
death,5 and they are also responsible for a large 
proportion of the health care costs attributable 
to this prevalent condition.6 Consequently, exac-
erbations are important outcomes in clinical tri-
als, and their prevention is a key component of 
COPD-management strategies.7
Despite the importance of exacerbations, we 
know relatively little about their incidence, their 
determinants, and their effects in patients with 
COPD at various levels of severity. Although exac-
erbations are generally considered to become more 
frequent as the severity of the underlying COPD 
increases, the most reliable predictor of exacer-
bations in an individual patient appears to be a 
history of exacerbations.8 There may therefore be 
a phenotype of exacerbation susceptibility that in-
cludes milder forms of COPD. However, this theo-
ry has not been adequately investigated because 
our current understanding of COPD exacerba-
tions and their relationship to disease severity is 
based on large intervention studies9,10 or multiple 
smaller studies that have used varying definitions 
of exacerbation.8 We used data from a large ob-
servational study to test the hypothesis that there 
is a frequent-exacerbation phenotype of COPD that 
is independent of disease severity.
Me thods
Study Design and Patients
This analysis was based on data collected as part 
of the Evaluation of COPD Longitudinally to Iden-
tify Predictive Surrogate Endpoints (ECLIPSE) ob-
servational study.11 The study was conducted in 
accordance with the Declaration of Helsinki and 
Good Clinical Practice guidelines. All patients 
provided written informed consent, and the study 
was approved by the relevant ethics and review 
boards.
The recruitment criteria included an age of 40 
to 75 years, a history of 10 or more pack-years of 
smoking, a forced expiratory volume in 1 second 
(FEV1) of less than 80% of predicted value after 
bronchodilator use, and a ratio of FEV1 to forced 
vital capacity (FVC) of 0.7 or less after broncho-
dilator use.
At baseline, patients underwent standard spi-
ro metry after the administration of 400 μg of in-
haled albuterol. Computed tomographic (CT) scan-
ning of the chest was performed to evaluate the 
severity and distribution of emphysema (for de-
tails, see the Supplementary Appendix, available 
with the full text of this article at NEJM.org). The 
condition of the patients was graded according to 
the stages of disease defined by the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD).12 
After the baseline visit, patients were followed for 
a total of seven visits: at 3 months, at 6 months, 
and every 6 months thereafter for 3 years.
The patients’ self-reported respiratory symp-
toms, medications, smoking history, occupational 
exposure, and coexisting medical conditions were 
documented at study entry with the use of the well-
established American Thoracic Society–Division 
of Lung Disease (ATS-DLD) questionnaire, which 
was updated for the purpose of this study.13
Serum and plasma samples were stored at 
−80°C until they were analyzed. Details of the 
assays are described in the Supplementary Appen-
dix. Any samples with values below the lower 
limit of quantification were assigned a value that 
was half of the lower limit.
A detailed description of methods can be found 
in the Supplementary Appendix. The study was 
conducted in accordance with the protocol, which 
is available at NEJM.org.
Study Outcomes
Exacerbations were a critical outcome. The case 
definition of an exacerbation was a functional one, 
based on the decision by a patient’s primary cli-
nician or by study personnel to prescribe antibi-
otics or systemic corticosteroids, alone or in com-
bination. Primary clinicians were not given a 
specific list of criteria that had to be met for an 
event to be classified as an exacerbation, but they 
were instructed to base their decision on common 
clinical criteria. This case definition therefore met 
the criteria for a definition of health care utiliza-
tion, and the exacerbations we recorded would be 
classified as moderate or severe in intensity.14 The 
case definition remained the same during the 
3 years of active data accrual, and identical criteria 
were applied retrospectively when we collected data 
from patients on the number of exacerbations they 
had had in the year before study enrollment.
Patient-reported measures at study entry in-
cluded assessments of dyspnea (made with the use 
of a modified Medical Research Council dyspnea 
The New England Journal of Medicine 
Downloaded from nejm.org at CRAI UNIVERSITAT DE BARCELONA on May 9, 2011. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 363;12 nejm.org september 16, 20101130
Table 1. Characteristics of the Patients According to the Severity of COPD.*
Characteristic
All Patients 
(N = 2138)
Moderate — 
GOLD Stage 2
(N = 945)
Severe — 
GOLD Stage 3
(N = 900)
Very Severe — 
GOLD Stage 4
(N = 293) P Value
Age (yr) 63±7 63±7 64±7 62±7 0.03
Female sex (%) 35 40 32 26 <0.001
Current smoker (%) 36 38 37 28 0.016
Body-mass index† 27±6 27±6 26±6 25±6 <0.001
FEV1 after bronchodilator use (liters) 1.35±0.52 1.75±0.45 1.13±0.27 0.72±0.16 <0.001
FEV1 after bronchodilator use (% of predicted 
value)
48±16 63±8 40±6 25±4 <0.001
FEV1:FVC (%) 45±12 53±9 40±9 32±8 <0.001
Distance walked in 6 min (m) 370±121 406±112 357±117 290±119 <0.001
BODE index‡ 3.2±2.1 1.6±1.4 4.0±1.6 5.7±1.6 <0.001
Emphysema  <0.001
Low attenuation areas (no.) 18±12 12±10 20±12 28±13 <0.001
Extent >5% of total area (%)§ 75 63 82 92 <0.001
Patient-reported outcomes‡
MRC dyspnea score ≥2 (%) 53 40 59 80 <0.001
CES depression score 11±9 11±9 12±9 13±10 0.002
FACIT fatigue score 35±11 37±10 34±11 32±11 <0.001
SGRQ for COPD, total score 50±20 42±21 54±18 62±16 <0.001
Medication for COPD (%)¶
Any long-acting bronchodilator 76 67 83 86 <0.001
Any inhaled corticosteroid 72 60 80 86 <0.001
Any methylxanthine 14  9 16 20 <0.001
Any leukotriene antagonist  3  3  4  3 0.51
Exacerbations
≥1 in preceding yr (%) 47 39 52 62 <0.001
≥2 in study yr 1 (%) 29 22 33 47 <0.001
Rate in yr 1 (no./patient) 1.21 0.85 1.34 2.00 <0.001
Requiring hospitalization 0.22 0.11 0.25 0.54 <0.001
Requiring oral corticosteroids only 0.14 0.10 0.15 0.21 <0.001
Requiring antibiotics only 0.44 0.37 0.46 0.60 <0.001
Requiring corticosteroids and antibiotics 0.41 0.27 0.47 0.65 <0.001
* Plus–minus values are means ±SD unless otherwise noted. The table includes data for the 56 patients who died (from any cause) during 
year 1 of the study; 16 had GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage 2 COPD, 26 had GOLD stage 3, and 14 had 
GOLD stage 4. FEV1 denotes forced expiratory volume in 1 second, and FVC forced vital capacity.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ The BODE index takes into account body-mass index, airway obstruction (as assessed on the basis of FEV1), dyspnea (as measured with the 
Medical Research Council [MRC] dyspnea scale), and exercise tolerance (as measured by a 6-minute walk test); scores range from 0 to 10. 
The Center for Epidemiologic Studies (CES) depression scale ranges from 0 to 60, with higher scores indicating more severe depression. 
The Functional Assessment of Chronic Illness Therapy (FACIT) fatigue scale ranges from 0 (most severe fatigue) to 52 (least severe fatigue). 
Scores on the St. George’s Respiratory Questionnaire (SGRQ) range from 0 (good health status) to 100 (poor health status). The MRC 
 dyspnea scale ranges from 0 (no dyspnea) to 4 (indicating that the patient is too breathless to leave home or becomes breathless when 
dressing or undressing) (a score of 4 indicates a minimally important clinical difference).
§ The extent of disease was evaluated by a radiologist.
¶ Information on medication was self-reported; patients may have been taking more than one medication.
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scale15), quality of life (St. George’s Respiratory 
Questionnaire for patients with COPD16), fatigue 
(Functional Assessment of Chronic Illness Thera-
py fatigue scale17), and depression (Center for Epi-
demiologic Studies depression scale18).
Statistical Analysis
Descriptive data are reported as means ±SD or per-
centages, as appropriate. Comparisons between 
groups for descriptive summaries were performed 
with the use of analysis of variance. The incidence 
of exacerbations was summarized as a per-person 
per-year rate. Differences in exacerbations between 
groups were analyzed with the use of a nonpara-
metric Kruskal–Wallis test. In the initial explora-
tion of data, exacerbations were analyzed as an 
indicator variable (a patient did have or did not 
have an exacerbation during year 1) fitting uni-
variate models with the use of logistic regression.
Multinomial logistic regression was performed 
with the use of PROC CATMOD in SAS, with the 
frequency of exacerbations during year 1 classi-
fied as none, one, or two or more to more fully 
characterize the associations between selected 
baseline factors and exacerbation frequency. We 
defined frequent exacerbations as two or more 
exacerbations in a year because this definition co-
incides with current health care utilization crite-
ria for frequent exacerbations. For the multivari-
ate analyses, a stepwise approach was used. All 
variables that were explored in the univariate 
analyses were considered in the multivariate mod-
el, with age, sex, smoking status, and body-mass 
index included as covariates in all models. A con-
servative significance threshold of 0.01 was used 
to determine the qualification of data for entry 
into or deletion from the model. All reported 
P values are nominal and two-sided and were not 
adjusted for multiple comparisons. Stepwise lo-
gistic regression was used for analyses involving 
patients with very severe COPD (GOLD stage 4). 
Biomarker data were log10-transformed before all 
regression analyses. All patients who underwent 
at least 30 days of follow-up were included in the 
regression analyses.
R esult s
Characteristics of the Patients
A total of 2164 patients were recruited for the 
study, and 2138 patients were enrolled and ob-
served during follow-up. The baseline character-
istics of the patients are reported in Table 1, cat-
egorized according to the severity of COPD. As 
the severity increased, exacerbations were both 
more frequent and more severe (Fig. 1). In the first 
year of follow-up, the exacerbation rates were 0.85 
per person for patients with moderate disease 
(GOLD stage 2), 1.34 for those with severe dis-
ease (GOLD stage 3), and 2.00 for those with very 
severe disease (GOLD stage 4). The severity of dis-
ease also affected hospitalization in year 1, with 
the proportion of patients who were hospitalized 
increasing with the severity of disease: GOLD 
stage 2, 7%; GOLD stage 3, 18%; and GOLD 
stage 4, 33%.
Factors Associated with Exacerbations
In univariate logistic-regression analysis, we as-
sessed factors associated with at least one exac-
erbation during the first year of follow-up, using 
all available baseline assessments in the whole 
cohort. The best predictor of an exacerbation in 
the first year was a treated exacerbation in the year 
before study entry (odds ratio, 4.30; 95% confi-
dence interval [CI], 3.58 to 5.17; P<0.001). Other 
variables significantly associated with exacerba-
tions are shown in Table 2.
Factors that were independently associated with 
exacerbations during the first year of follow-up, 
on the basis of a multinomial regression model, 
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Figure 1. Association of Disease Severity with the Frequency and Severity  
of Exacerbations during the First Year of Follow-up in Patients with Chronic 
Obstructive Pulmonary Disease.
Patients with two or more exacerbations during the year were considered to 
have frequent exacerbations. An exacerbation requiring hospitalization was 
classified as severe. Disease severity was classified according to the stages 
of disease defined by the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD). P<0.001 for both comparisons.
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Table 2. Univariate Associations with the Occurrence of Exacerbations during the First Year of Follow-up.*
Baseline Characteristics Odds Ratio (95% Wald CI) P Value
Demographic and clinical characteristics
Self-reported exacerbation during preceding yr — yes vs. no 4.30 (3.58–5.17) <0.001
BODE index — per increase of 1 point 1.23 (1.18–1.28) <0.001
MRC dyspnea score — 2, 3, or 4 vs. 0 or 1 1.83 (1.54–2.18) <0.001
Distance walked in 6 min — per decrease of 50 m 1.12 (1.08–1.16) <0.001
Post-secondary (or higher) education level — yes vs. no 0.70 (0.58–0.83) <0.001
Fat-free mass index — per increase of 1 point 0.93 (0.90–0.97) <0.001
Sex — female vs. male 1.42 (1.19–1.71) <0.001
Body-mass index — per increase of 1 point 0.98 (0.97–1.00) 0.03
Age — per 10-year increase 1.14 (1.01–1.28) 0.04
Smoking status — current vs. former smoker 0.83 (0.70–0.99) 0.04
Lung function
FEV1 — per 100-ml decrease 1.11 (1.10–1.14) <0.001
FEV1 — per 5% decrease in % of predicted value 1.15 (1.11–1.18) <0.001
GOLD stage — per increase to next stage 1.74 (1.53–1.97) <0.001
FEV1:FVC — per 1% decrease 1.03 (1.02–1.04) <0.001
FVC — per 100-ml decrease 1.04 (1.03–1.05) <0.001
Emphysema 
Per 5% increase in low-attenuation areas 1.16 (1.11–1.20) <0.001
Radiologic score >5% — yes vs. no 1.79 (1.45–2.21) <0.001
Patient-reported outcomes
SGRQ score for COPD — per 4-point worsening 1.10 (1.08–1.12) <0.001
FACIT score for fatigue — per 1-point worsening 1.03 (1.02–1.04) <0.001
CES score for depression — per 1-point worsening 1.03 (1.02–1.04) <0.001
Laboratory values
Platelet count — per increase of 10×103/mm3 1.02 (1.01–1.04) <0.001
White-cell count — per increase of 1×103/mm3 1.07 (1.03–1.12) <0.001
Neutrophil count — per increase of 1×103/mm3 1.02 (1.01–1.03) <0.001
Biomarkers†
Fibrinogen — mg/dl 1.35 (1.22–1.49) <0.001
High-sensitivity C-reactive protein — mg/liter 1.24 (1.13–1.37) <0.001
Chemokine ligand 18 — ng/ml 1.13 (1.02–1.25) 0.02
Surfactant protein D — ng/ml 1.10 (1.01–1.20) 0.04
Self-reported symptoms and disease history — yes vs. no‡
Gastroesophageal reflux or heartburn 1.69 (1.38–2.06) <0.001
Wheezing 1.56 (1.31–1.86) <0.001
Osteoporosis 1.74 (1.34–2.27) <0.001
Asthma 1.52 (1.23–1.87) <0.001
Chronic cough 1.20 (1.01–1.42) 0.04
* The full version of this table, including all baseline characteristics, is available in the Supplementary Appendix. Only signifi-
cant variables are listed. Nonsignificant variables included other clinical data (number of pack-years of smoking), other 
laboratory values (percentage of blood eosinophils and hemoglobin), other biomarker data (interleukin-6, interleukin-8, 
Clara cell protein-16, and tumor necrosis factor α), and other data on self-reported symptoms and disease history (hyper-
tension, hay fever, chronic bronchitis or chronic phlegm production, “lung trouble” before 16 years of age, exposure to 
chemical fumes or dusts at work, and cardiovascular and sinus disease). BODE denotes body-mass index, (airway) ob-
struction, dyspnea, and exercise tolerance; CES Center for Epidemiologic Studies; FACIT Functional Assessment of Chronic 
Illness Therapy; FEV1 forced expiratory volume in 1 second; FVC forced vital capacity; GOLD Global Initiative for Chronic 
Obstructive Lung Disease; MRC Medical Research Council; and SGRQ St. George’s Respiratory Questionnaire.
†  The increment for biomarker changes was 1 SD on the log scale.
‡  Data on self-reported history are based on subjects’ responses to the ATS-DLD questionnaire.
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are shown in Table 3. Exacerbations were signifi-
cantly associated with worsening lung function 
(according to post-bronchodilator FEV1), greater 
impairment in health status (quality of life), a his-
tory of gastroesophageal reflux, and an increased 
white-cell count.
Stability of the Frequent-Exacerbation 
Phenotype
To assess the stability of the frequent-exacerbation 
phenotype over time, we first assessed how well 
patients’ recall of treated exacerbations in the year 
before study entry predicted the number of exac-
erbations in year 1, calculating positive predic-
tive values and negative predictive values. These 
analyses included data from the 1679 patients who 
completed all 3 years of the study.
Among the 1318 patients reporting no exacer-
bation or one exacerbation in the year before en-
rollment (infrequent exacerbations), 1037 also had 
infrequent exacerbations in the first year of the 
study (negative predictive value, 79%). Among the 
361 patients reporting two or more exacerbations 
in the year before enrollment (frequent exacerba-
tions), 211 also had frequent exacerbations in the 
first year of the study (positive predictive value, 
58%); 289 of these patients (80%) had at least one 
exacerbation. Previous exacerbation frequency as 
recalled by patients therefore had a sensitivity of 
43% and a specificity of 87% for actual exacerba-
tion frequency in the following year.
We next examined the stability of exacerbation 
frequency between study years 1 and 2. Among 
the 1187 patients with infrequent exacerbations 
during year 1, a total of 987 had infrequent ex-
acerbations in year 2 (negative predictive value, 
83%). Among the 492 patients with frequent exac-
erbations in year 1, there were 296 who had fre-
quent exacerbations in year 2 (positive predictive 
value, 60%); 84% of patients with frequent exac-
erbations in year 1 had at least one exacerbation 
in year 2. Thus, exacerbation frequency in the first 
year had a sensitivity of 60% and a specificity of 
83% for the frequency in the second year.
Among the 1183 patients with infrequent ex-
acerbations in year 2 of the study, 994 also had 
infrequent exacerbations in year 3 (negative pre-
dictive value, 84%). Among the 496 patients with 
frequent exacerbations in year 2, there were 276 
who had frequent exacerbations in year 3 (positive 
predictive value, 56%).
Over the three-year study period, the pheno-
types for exacerbation susceptibility and resistance 
became stronger. Among 296 patients who had 
frequent exacerbations in years 1 and 2, there 
were 210 (71%) who went on to have frequent 
exacerbations in year 3, and among 521 patients 
with no exacerbation in year 1 or year 2, a total 
of 388 (74%) also had no exacerbation in year 3. 
The stability of exacerbation frequency is shown 
in Figure 2.
Exacerbation Frequency According to 
Disease Severity
Among the 945 patients with moderate COPD, 208 
(22%) had frequent exacerbations (two or more 
during the first year of the study). (The character-
istics of patients with moderate COPD are listed 
Table 3. Factors Associated with Increased Exacerbation Frequency in the Stepwise Multivariate Model.*
Factor Number of Exacerbations
P Value for 
Overall Model
≥2 vs. 0 1 vs. 0 ≥2 vs. 1
odds ratio
(95% CI) P value
odds ratio 
(95% CI) P value
odds ratio 
(95% CI) P value
Exacerbation during previous yr —  
any vs. none
5.72 (4.47–7.31) <0.001 2.24 (1.77–2.84) <0.001 2.55 (1.96–3.31) <0.001 <0.001
FEV1 — per 100-ml decrease 1.11 (1.08–1.14) <0.001 1.06 (1.03–1.08) <0.001 1.05 (1.02–1.09) <0.001 <0.001
SGRQ score for COPD — per  
increase of 4 points
1.07 (1.04–1.10) <0.001 1.01 (0.99–1.04) 0.38 1.06 (1.03–1.09) <0.001 <0.001
History of reflux or heartburn —  
yes vs. no
2.07 (1.58–2.72) <0.001 1.61 (1.23–2.10) <0.001 1.29 (0.97–1.70) <0.005 <0.001
White-cell count — per increase  
of 1×103/mm3
1.08 (1.03–1.14) 0.002 1.02 (0.97–1.08) 0.45 1.06 (1.01–1.12) <0.001 0.007
* FEV1 denotes forced expiratory volume in 1 second, and SGRQ St. George’s Respiratory Questionnaire.
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according to exacerbation frequency in Table 1 in 
the Supplementary Appendix.) To further charac-
terize patients with moderate COPD who had the 
frequent-exacerbation phenotype, we repeated the 
stepwise multinomial regression analysis, this 
time including only these patients. Because there 
was a high degree of confounding with sex in 
this model, associations were explored for each 
sex separately. The results are reported in Table 4. 
Exacerbations were significantly more common 
in women with moderate COPD than in men with 
moderate COPD: 1.02 versus 0.74 exacerbations 
per person per year (P<0.001). As in the full co-
hort, among both men and women, the variable 
most strongly associated with exacerbations dur-
ing the first year of follow-up was a history of 
exacerbations. A greater impairment in health sta-
tus (quality of life) was associated with exacerba-
tions in the overall cohort of patients with mod-
erate COPD, but the association was not observed 
in the models in which each sex was analyzed 
separately.
Among the 293 patients in the study who had 
very severe COPD, 138 (47%) had frequent exac-
erbations (two or more) during the first year of the 
study, and 84 (29%) had no exacerbations. (The 
characteristics of patients with very severe COPD, 
categorized according to exacerbation frequency, 
are listed in Table 2 in the Supplementary Ap-
pendix.) In a stepwise logistic-regression analy-
sis, the patients with very severe COPD who did 
not have exacerbations during the 3-year study 
period were those who did not have exacerbations 
in the year before study entry (odds ratio, 4.53; 
95% CI, 2.62 to 7.82; P<0.001). No other variables 
were significantly associated with exacerbations, 
and in this group of patients, there was no asso-
ciation between exacerbation frequency and health 
status (as assessed with the use of the St. George’s 
Respiratory Questionnaire). (The characteristics 
of patients with severe COPD, categorized accord-
ing to exacerbation frequency, are listed in Ta-
bles 3 and 4 in the Supplementary Appendix).
Discussion
Using data from the large observational ECLIPSE 
cohort, we examined the frequency of exacerba-
tions among patients with moderate, severe, or very 
severe COPD. We found that one group of pa-
tients appeared to be susceptible to exacerbations, 
irrespective of disease severity as defined by spiro-
metric assessment of lung function. This pheno-
type of susceptibility to exacerbations could be 
identified by asking patients about previous ex-
acerbations and was relatively stable over a 3-year 
period.
A range of variables have inconsistently been 
associated with exacerbation frequency in previ-
ous studies.8-10 We have provided robust data from 
a single study showing that exacerbations requir-
ing treatment become more frequent as the se-
verity of COPD increases. Our study concerns 
moderate and severe exacerbations, which are the 
most burdensome to patients and health care ser-
vices, among patients with a wide spectrum of 
COPD severity and in whom the underlying dis-
ease has been comprehensively assessed. Our con-
servative definition of exacerbation probably un-
derestimates the frequency of symptom-defined 
events.8 Nevertheless, the proportion of patients 
with GOLD stage 4 disease who had frequent ex-
acerbations (two or more annually) was more than 
twice the proportion of patients with GOLD stage 
2 disease who had frequent exacerbations. Our 
data also support the view that the consequences 
of exacerbation become more severe with increas-
ing disease severity. However, differentiating the 
severity of exacerbations from the severity of the 
underlying disease is complex.
The major determinant of frequent exacerba-
tions in all GOLD stages of COPD severity that we 
examined was a history of exacerbations. Our re-
sults suggest that COPD with frequent exacerba-
tions is a distinct phenotype that is seen in mod-
erate and severe stages of disease and that the 
incidence of frequent exacerbations increases with 
increasing disease severity. We use the term “dis-
tinct” in reference to a subgroup of patients who 
appear to be particularly susceptible to these 
events, accepting that exacerbation frequency is 
a continuous variable. There is currently much in-
terest in defining specific phenotypes in COPD 
that may have different prognoses or treatment 
requirements.19 Our data suggest that the frequent-
exacerbation phenotype can be identified on the 
basis of a history of exacerbations, potentially 
allowing for appropriate targeting of patients for 
interventions and making it possible to selec-
tively recruit patients for clinical trials. Status 
with respect to exacerbation frequency appears 
to be relatively stable over time, especially in the 
case of patients who do not have exacerbations. 
This suggests that the phenotype of frequent ex-
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Figure 2. Stability of the Frequent-Exacerbation Phenotype in the 1679 Patients with Chronic Obstructive Pulmonary Disease Who Completed 
the Study.
The bars at the left show the proportions of patients with no exacerbations, one exacerbation, or two or more exacerbations in year 1. 
The bars in the middle show the respective incidence of exacerbations for these patients in year 2; the bars at the right show the respec-
tive incidence in year 3. The percentages at right denote the proportions of all patients with no exacerbations, one exacerbation, or two 
or more exacerbations. Numbers do not sum to 100 because of rounding.
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acerbations may best be described as an exacerba-
tion-susceptibility phenotype, in which persons 
with the phenotype are prone to exacerbations as 
a result of intrinsic susceptibility and have exacer-
bations on exposure to particular triggers, such 
as respiratory viral infection.20
In the multivariate analysis of data for the en-
tire cohort, in addition to the association with 
previous exacerbations and with greater disease 
severity, more frequent exacerbations were associ-
ated with greater impairment in health status, 
a history of gastroesophageal reflux, and an el-
evated white-cell count. Sex was associated with 
exacerbation frequency, but it was confounded 
with other variables. It has previously been re-
ported that patients with frequent exacerbations 
may have increased airway inflammation in the 
stable state.21 The relationship that we observed 
between exacerbation frequency and health sta-
tus has been noted previously,4 as has the asso-
ciation of exacerbations with gastroesophageal 
reflux.22 In contrast, chronic bronchitis was not 
associated with exacerbations in any of our analy-
ses, despite previous reports that cough and spu-
tum production are related to exacerbations in 
COPD.23-25
Among the patients who had moderate COPD, 
22% had frequent exacerbations –– an important 
observation, considering that such patients, who 
have relatively mild disease according to FEV1 
criteria, may not at present be identified for in-
terventions to reduce exacerbations. Since mod-
erate COPD is more prevalent than very severe 
COPD,26 the overall burden of exacerbations may 
be greater with milder disease. In the group of 
patients with moderate disease in our study, ex-
acerbations were more common among women 
than among men, and there were other factors 
that varied according to sex. The observation of 
sex-based differences in exacerbation frequency is 
intriguing, and it is not clear whether the higher 
rate of exacerbations among women represents 
a real increase in exacerbations, women’s height-
ened awareness of symptoms, or a greater ten-
dency on the part of women to report such 
changes in symptoms to a health care provider. 
Regarding features that could suggest airway hy-
perreactivity, such as wheezing or a history of 
asthma, bronchodilator reversibility criteria were 
not used as criteria for inclusion or exclusion in 
the ECLIPSE study. The question of whether clini-
cally significant airway hyperresponsiveness is 
also a distinct phenotype in COPD requires fur-
ther study.
Among the patients in the study who had very 
severe COPD, 29% appeared to have had resis-
tance to exacerbations, although some of these 
patients may have been unable to recognize an 
Table 4. Factors Associated with Increased Exacerbation Frequency in Patients with Moderate (GOLD Stage 2) COPD, According to Sex.
Factor Number of Exacerbations
Overall 
P Value
≥2 vs. 0 1 vs. 0 ≥2 vs. 1
odds ratio 
(95% CI) P value
odds ratio 
(95% CI) P value
odds ratio 
(95% CI) P value
Women (N = 376)
Exacerbation during previous year —  
yes vs. no
8.89 (4.32–18.29) <0.001 2.28 (1.26–4.11) <0.006 3.90 (1.82–8.34) <0.001 <0.001
History of asthma — yes vs. no 3.38 (1.62–7.05) <0.001 3.00 (1.59–5.66) <0.001 1.12 (0.53–2.38) 0.76 <0.001
Fibrinogen — per increase of 1 SD  
on log scale
1.95 (1.28–2.97) <0.002 1.22 (0.85–1.74) 0.28 1.60 (1.03–2.49) <0.04 0.008
Men (N = 569)
Exacerbation during previous yr —  
yes vs. no
7.38 (4.44–12.27) <0.001 3.28 (2.09–5.13) <0.001 2.25 (1.30–3.90) 0.004 <0.001
FEV1 — per 100-ml decrease* 1.20 (1.11–1.31) <0.001 1.07 (1.00–1.14) <0.05 1.13 (1.04–1.23) <0.006 <0.001
Chronic wheezing — yes vs. no 2.56 (1.55–4.23) <0.001 1.40 (0.89–2.18) 0.14 1.83 (1.06–3.16) <0.03 0.001
* FEV1 denotes forced expiratory volume in 1 second, and NS not significant.
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exacerbation (which may therefore not have been 
reported to their physician for treatment).4,27 This 
finding also has potential implications for thera-
py, in that it may not be necessary to take aggres-
sive approaches to the prevention of exacerbations 
in patients with very severe COPD if they do not 
have a history of such events. In our study, patients 
with very severe disease who did not have exacer-
bations did not have any other characteristics dis-
tinguishing them from patients with exacerba-
tions except for the fact that they did not report 
exacerbations in the preceding year.
Although exacerbation frequency was associat-
ed with health status across the GOLD stages and 
in patients with moderate (stage 2) disease, this 
was not true among patients with the most se-
vere disease (stage 4). Whether this trend reflects 
the smaller number of patients with very severe 
disease or a survivor effect among patients with 
severe disease who were participating in a longi-
tudinal study cannot be established. Another pos-
sibility is that in patients with very severe COPD, 
the role of exacerbations in compromising health 
status is less important than that of the severity 
of the underlying disease itself.
The main strength of this analysis is the use of 
a large cohort of patients with COPD and a range 
of disease severity. Some important negative 
findings deserve mention — in particular, the fact 
that we did not find an association between smok-
ing status and exacerbation frequency.4 However, 
our cohort was not a population sample but a 
sample of symptomatic patients known to respi-
ratory physicians. Controlled trials have shown 
that pharmacotherapy can reduce exacerbations.9,10 
We did not focus on medication as a determinant 
of exacerbations. Evidence-based treatment of 
COPD often includes the use of a history of ex-
acerbation as an indicator for starting treatment12; 
in an observational study, exacerbations are there-
fore likely to predict treatment — not vice versa.
In conclusion, our study confirms the obser-
vation that exacerbations become more frequent 
and more severe as the severity of underlying 
COPD increases and shows that the most impor-
tant determinant of frequent exacerbations is a 
history of exacerbations. This finding supports 
the hypothesis that patients who are more subject 
to frequent exacerbations, some of whom have 
milder disease, have a distinct susceptibility phe-
notype that is relatively stable over time and can 
be identified on the basis of the patient’s recall 
of previously treated events.
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